| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US9539241 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jan, 2028
(3 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9205075 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jul, 2026
(2 years from now) | |
| US8186511 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Jul, 2026
(2 years from now) | |
| US7806265 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
Feb, 2029
(4 years from now) | |
| US9649428 | MOBIUS THERAP | Apparatus and method for reconstituting a pharmaceutical and preparing the reconstituted pharmaceutical for transient application |
May, 2029
(5 years from now) | |
Mitosol is owned by Mobius Therap.
Mitosol contains Mitomycin.
Mitosol has a total of 5 drug patents out of which 0 drug patents have expired.
Mitosol was authorised for market use on 07 February, 2012.
Mitosol is available in for solution;topical dosage forms.
Mitosol can be used as mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery.
The generics of Mitosol are possible to be released after 21 May, 2029.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-21) | Feb 07, 2019 |
| Orphan Drug Exclusivity(ODE) | Feb 07, 2019 |
Drugs and Companies using MITOMYCIN ingredient
Market Authorisation Date: 07 February, 2012
Treatment: Mitosol is an antimetabolite indicated as an adjunct to ab externo glaucoma surgery. it is intended for topical application to the site of glaucoma filtration surgery
Dosage: FOR SOLUTION;TOPICAL
MITOSOL family patents
